Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Itzykson

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Cancers|October 13, 2021
Clonal Architecture and Evolutionary Dynamics in Acute Myeloid LeukemiasMatthieu Duchmann, Lucie Laplane, Raphael Itzykson
Seminars in Hematology|October 20, 2012
Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidineLionel Adès, Raphael Itzykson, Pierre Fenaux
Best Practice & Research. Clinical Haematology|February 11, 2014
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromesRaphael Itzykson, Olivier Kosmider, Pierre Fenaux
Experimental Hematology|July 1, 2015
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomideClémence Loiseau, Ashfaq Ali, Raphael Itzykson
Best Practice & Research. Clinical Haematology|February 11, 2014
Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?Raphael Itzykson, Raphael Itzkson, Pierre Fenaux, et al.
International Journal of Hematology|April 30, 2017
CMML: Clinical and molecular aspectsRaphael Itzykson, Matthieu Duchmann, Nolwenn Lucas, et al.
Oncotarget|January 19, 2013
Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemiaVirginie Chesnais, Olivier Kosmider, Frederik Damm, et al.
Blood Reviews|February 12, 2022
Endothelial cells: major players in acute myeloid leukaemiaSofiane Fodil, Marine Arnaud, Camille Vaganay, et al.
American Journal of Hematology|March 6, 2014
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemiaNathalie Cervera, Raphael Itzykson, Emilie Coppin, et al.
Haematologica|April 5, 2011
Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaRaphael Itzykson, Claude Gardin, Cécile Pautas, et al.
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Cancers|October 13, 2021
Clonal Architecture and Evolutionary Dynamics in Acute Myeloid LeukemiasMatthieu Duchmann, Lucie Laplane, Raphael Itzykson
Seminars in Hematology|October 20, 2012
Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidineLionel Adès, Raphael Itzykson, Pierre Fenaux
Best Practice & Research. Clinical Haematology|February 11, 2014
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromesRaphael Itzykson, Olivier Kosmider, Pierre Fenaux
Experimental Hematology|July 1, 2015
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomideClémence Loiseau, Ashfaq Ali, Raphael Itzykson
Best Practice & Research. Clinical Haematology|February 11, 2014
Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?Raphael Itzykson, Raphael Itzkson, Pierre Fenaux, et al.
International Journal of Hematology|April 30, 2017
CMML: Clinical and molecular aspectsRaphael Itzykson, Matthieu Duchmann, Nolwenn Lucas, et al.
Oncotarget|January 19, 2013
Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemiaVirginie Chesnais, Olivier Kosmider, Frederik Damm, et al.
Blood Reviews|February 12, 2022
Endothelial cells: major players in acute myeloid leukaemiaSofiane Fodil, Marine Arnaud, Camille Vaganay, et al.
American Journal of Hematology|March 6, 2014
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemiaNathalie Cervera, Raphael Itzykson, Emilie Coppin, et al.
Haematologica|April 5, 2011
Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaRaphael Itzykson, Claude Gardin, Cécile Pautas, et al.
Pageof 10